How cancer cells use exosomes to evade the immune system
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep the immune system from fighting tumors, which might help explain why some people respond better to certain cancer treatments than others, with the hope of creating more personalized and effective treatment options for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10671960 on NIH RePORTER |
What this research studies
This research investigates how cancer cells utilize exosomes to package immune checkpoint proteins, specifically PD-L1, which can suppress the immune response against tumors. By understanding the mechanisms behind this process, the research aims to identify why some patients respond well to immune checkpoint inhibitors while others do not. The team of experts will explore the role of exosomal PD-L1 in cancer progression and resistance to therapies, with the goal of personalizing cancer treatments based on individual responses. This could lead to more effective strategies for managing cancer and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who are undergoing treatment with immune checkpoint inhibitors.
Not a fit: Patients with cancers that do not involve immune checkpoint pathways or those who are not receiving immune checkpoint therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that are tailored to individual patients, enhancing their chances of remission.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune checkpoint proteins in cancer therapy, indicating that this approach has potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Blelloch, Robert — University of California, San Francisco
- Study coordinator: Blelloch, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.